MME and heart failure: Lcz696 (valsartan/sacubitril), the first of the new ARNI (dual-acting angiotensin-receptor–neprilysin inhibitor) drug class, contains equimolar amounts of valsartan which is an angiotensin-receptor blocker, and sacubitril, which is a prodrug for the neprilysin inhibitor, and ARNI has been extensively reported to approve for the treatment of heart failure patients with reduced ejection fraction [ (Campbell, 2017).